Hope for pancreatic cancer as new drug, daraxonrasib, shows promise
In 1988, a landmark paper appeared in the journal Cell. It showed that in around 95% of pancreatic cancers, a gene called KRAS carried mutations at a particular location. The paper was a watershed moment in cancer research since it was one of the first demonstrations of a mutation with near-universal frequency identified in a…
Read More “Hope for pancreatic cancer as new drug, daraxonrasib, shows promise” »
